Literature DB >> 3171627

Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis.

N Cohen1, G Strauss, R Lew, D Silver, L Recht.   

Abstract

We analyzed a retrospective series of 195 patients with documented intracerebral metastases (ICM) to assess the frequency of late seizure development and the impact of prophylactic anticonvulsants. Eighteen percent of the patients presented with seizures. Of the remaining patients, 40% received prophylactic anticonvulsants (diphenylhydantoin [DPH] in greater than 90%). Ten percent developed late seizures at an interval from the diagnosis of ICM ranging from 1 to 59 weeks. No patient with a posterior fossa lesion developed seizure; conversely, patients with evidence on initial examination of cerebral hemispheric dysfunction had a higher incidence of late seizure development. The incidence of seizure was virtually identical in patients who received DPH compared with those in whom it was withheld, although two thirds of patients who developed seizure while on DPH had a serum anticonvulsant level that was subtherapeutic. Based on the above findings and until prospective data become available, we recommend that anticonvulsants be withheld in newly-diagnosed patients with ICM until the first seizure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3171627     DOI: 10.1200/JCO.1988.6.10.1621

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  24 in total

1.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

Authors:  Leandro C A Cerchietti; Marcelo R Bonomi; Alfredo H Navigante; Monica A Castro; Maria E Cabalar; Berta M C Roth
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

Review 2.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 3.  Clinical management of brain metastasis.

Authors:  C J Vecht
Journal:  J Neurol       Date:  1998-03       Impact factor: 4.849

Review 4.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

Review 5.  Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery?

Authors:  Alexander Muacevic; Michael Siebels; Jörg-Christian Tonn; Berndt Wowra
Journal:  World J Urol       Date:  2005-03-25       Impact factor: 4.226

Review 6.  Optimal seizure management in brain tumor patients.

Authors:  Melanie S M van Breemen; Charles J Vecht
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

7.  Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience.

Authors:  Shelly Lwu; Mark G Hamilton; Peter A Forsyth; J Gregory Cairncross; Ian F Parney
Journal:  J Neurooncol       Date:  2009-08-08       Impact factor: 4.130

Review 8.  Seizure prophylaxis for brain tumour patients. Brief review and guide for family physicians.

Authors:  C B Agbi; M Bernstein
Journal:  Can Fam Physician       Date:  1993-05       Impact factor: 3.275

Review 9.  Treatment options for brain metastases in patients with non-small-cell lung cancer.

Authors:  Sadaf Taimur; Martin J Edelman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

Review 10.  Current advances in understanding and managing secondary brain metastasis.

Authors:  Radhika Dasararaju; Amitkumar Mehta
Journal:  CNS Oncol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.